Endoprevention of esophageal cancer: Endoscopic ablation of Barrett's metaplasia and dysplasia

Expert Review of Medical Devices

Volumn 2, Issue 6, 2005, Pages 713-723

  Wolfsen, Herbert C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Argon beam coagulation; Cryoablation; Endoscopic mucosal resection; Multipolar electrocoagulation; Photodynamic therapy; Porfimer sodium; Radiofrequency ablation

Indexed keywords

AMINOLEVULINIC ACID; ARGON; NEODYMIUM; NITROGEN; OMEPRAZOLE; PHOTOFRIN; PREDNISONE; PROTEIN P53; PROTON PUMP INHIBITOR; TETRAKIS(3 HYDROXYPHENYL)CHLORIN;

ADENOMATOUS POLYP; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; BEAM THERAPY; BLEEDING; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 16P; CLINICAL TRIAL; COLON POLYP; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CYTOMETRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA DETERMINATION; DOSIMETRY; DRUG SAFETY; DYSPLASIA; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SURGERY; ENDOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HEART FAILURE; HEART INFARCTION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; IMAGING SYSTEM; INCIDENCE; INTESTINE RESECTION; LAPAROTOMY; LASER SURGERY; LENGTH OF STAY; LOW DRUG DOSE; METAPLASIA; METHYLATION; MORTALITY; NEODYMIUM LASER; PATIENT SATISFACTION; PERFORATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PNEUMONIA; POLYPECTOMY; POSTOPERATIVE COMPLICATION; PREDICTION; PREVALENCE; RADIOFREQUENCY RADIATION; RECURRENCE RISK; REMISSION; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL EQUIPMENT; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THERMAL STIMULATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; WOUND INFECTION;

EID: 28244498738     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2.6.713     Document Type: Review

References (103)

1. Bond JH. Interference with the adenomacarcinoma sequence. Eur. J. Cancer 31A, 1115-1117 (1995).
2. Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 329, 1977-1981 (1993).
3. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am. J. Gastroenterol. 95, 868-877 (2000).
4. US Preventative Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann. Intern. Med. 137, 129-131 (2002).
5. Wolfsen HC. Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. J. Clin. Gastroenterol. 39, 189-202 (2005).
6. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. Cancer J. Clin. 55, 10-30 (2005).
7. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 11, 235-256 (2002).
8. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J. Am. Med. Assoc. 265, 1287-1289 (1991).
9. Pacifico RJ, Wang KK. Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surg. Oncol. Clin. N. Am. 11, 321-336 (2002).
10. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 128, 1554-1566 (2005).
11. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am. J. Gastroenterol. 92, 212-215 (1997).
12. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am. J. Gastroenterol. 96, 1355-1362 (2001).
13. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 95, 1669-1676 (2000).
14. Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 95, 3383-3387 (2000).
15. da Silva VD, Prolla JC, Sharma P, Sampliner R, Thompson D, Bartels PH. Karyometry in Barrett's esophagus. Anal. Quant. Cytol. Histol. 23, 40-46 (2001).
16. Garewal HS, Sampliner R, Liu Y, Trent JM. Chromosomal rearrangements in Barrett's esophagus. A premalignant lesion of esophageal adenocarcinoma. Cancer Genet. Cytogenet. 42, 281-286 (1989).
17. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 3, 676-684 (2003).
18. Olliver JR, Hardie LJ, Gong Y et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 14, 620-625 (2005).
19. Urbach DR, Baxter NN. Does it matter what a hospital is "high volume" for? Specificity of hospital volume-outcome associations for surgical procedures: analysis of administrative data. Br. Med. J. 328, 737-740 (2004).
20. Bartels H, Stein HJ, Siewert JR. Risk analysis in esophageal surgery. Recent Results Cancer Res. 155, 89-96 (2000).
21. Dimick JB, Wainess RM, Upchurch GR Jr, Iannettoni MD, Orringer MB. National trends in outcomes for esophageal resection. Ann. Thorac. Surg. 79, 212-216 (2005).
22. Lerut TE, van Lanschot JJ. Chronic symptoms after subtotal or partial oesophagectomy diagnosis and treatment. Best Pract. Res. Clin. Gastroenterol. 18, 901-915 (2004).
23. Orringer MB, Marshall B, Iannettoni MD. Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J. Thorac. Cardiovasc. Surg. 119, 277-288 (2000).
24. Ikeguchi M, Maeta M, Kaibara N. Respiratory function after esophagectomy for patients with esophageal cancer. Hepatogastroenterology 49, 1284-1286 (2002).
25. Shibuya S, Fukudo S, Shineha R et al. High incidence of reflux esophagitis observed by routine endoscopic examination after gastric pull-up esophagectomy. World J. Surg. 27, 580-583 (2003).
26. Wolfsen HC, Hemminger LL, DeVault KR. Recurrent Barrett's esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterol. 4, 18 (2004).
27. De Leyn P, Coosemans W, Lerut T. Early and late functional results in patients with intrathoracic gastric replacement after oesophagectomy for carcinoma. Eur. J. Cardiothorac. Surg. 6, 79-84 (1992).
28. DeVault KR, Ward EM, Wolfsen HC et al. Barrett's esophagus (BE) is common in older patients undergoing screening colonoscopy regardless of gastroesophageal reflux (GER) symptoms. Gastrointest. Endosc. 59, AB111 (2004).
29. Conio M, Lapertosa G, Blanchi S, Filiberti R. Barrett's esophagus: an update. Crit. Rev. Oncol. Hematol. 46, 187-206 (2003).
30. Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br. J. Surg. 38, 175-182 (1950).
31. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N. Engl. J. Med. 313, 857-859 (1985).
32. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825-831 (1999).
33. Sampliner RE. Long-term endoscopic surveillance of Barrett's esophagus. Am. J. Gastroenterol. 98, 1912-1913 (2003).
34. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122, 633-640 (2002).
35. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122, 26-33 (2002).
36. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastrooesophageal reflux. Gut 53, 1070-1074 (2004).
37. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123, 461-467 (2002).
38. Rex DK, Cummings OW, Shaw M et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125, 1670-1677 (2003).
39. DeVault KR, Ward EM, Wolfsen HC et al. Symptoms do not predict the presence of Barrett's esophagus in older patients undergoing colonoscopy. Am. J. Gastroenterol. 98, S13 (2003).
40. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99, 918-922 (1990).
41. Ormsby AH, Kilgore SP, Goldblum JR, Richter JE, Rice TW, Gramlich TL. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod. Pathol. 13, 614-620 (2000).
42. Wolfsen HC, Hemminger LL, DeVault KR. Barrett's dysplasia and mucosal carcinoma patients referred for photodynamic therapy - do they come from surveillance programs? Gastrointest. Endosc. 59, AB265 (2004).
43. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann. Intern. Med. 138, 176-186 (2003).
44. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am. J. Gastroenterol. 94, 2043-2053 (1999)
45. Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 35, 1059-1068 (2003).
46. Dulai G, Jensen D, Saad M, Mawas I, Yu J, Fontana L. Simultaneous screening for Barrett's and colorectal cancer. Gastrointest. Endosc. 59, AB259 (2004).
47. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology 37, 99-107 (2000).
48. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. J. Am. Med. Assoc. 287, 1972-1981 (2002).
49. Gross CP, Cruz-Correa M, Canto MI, McNeil-Solis C, Valente TW, Powe NR. The adoption of ablation therapy for Barrett's esophagus: a cohort study of gastroenterologists. Am. J. Gastroenterol. 97, 279-286 (2002).
50. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120, 1607-1619 (2001).
51. Fang M, Lew E, Klein M, Sebo T, Su Y, Goyal R. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. Am. J. Gastroenterol. 99, 1887-1894 (2004).
52. Siersema PD. Endoscopic therapeutic esophageal interventions: something old, something new, something to be established. Curr. Opin. Gastroenterol. 20, 397-403 (2004).
53. Wang K. Photodynamic therapy made simple. Clin. Perspec. Gastroenterol. 90-100 (2001).
54. Webber J, Herman M, Kessel D, Fromm D. Current concepts in gastrointestinal photodynamic therapy. Ann. Surg. 230, 12-23 (1999).
55. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest. Endosc. 49, 1-7 (1999).
56. Malhi-Chowla N, Wolfsen HC, DeVault KR. Esophageal dysmotility in patients undergoing photodynamic therapy. Mayo Clin. Proc. 76(10), 987-989 (2001).
57. Wolfsen HC, Hemminger LL. Photodynamic therapy for dysplastic Barrett's esophagus and mucosal adenocarcinoma. Gastrointest. Endosc. 59, AB251 (2004).
58. Wang KK, Wong Kee Song LM, Buttar NS, Papenfuss S, Lutzke L. Barrett's esophagus after photodynamic therapy: risk of cancer development during long term follow up. Gastroenterology 126(Suppl. 2), A50 (2004).
59. Ukleja A, Scolapio JS, Wolfsen HC. Endoscopic ultrasonography (EUS) and endoscopic mucosal resection (EMR) for staging and treatment of high-grade dysplasia (HGD) and early adenocarcinoma (EAC) in Barrett's esophagus (BE). Gastrotenterology 116, A582 (1999).
60. Nijhawan PK, Wolfsen HC, Wang KK, Buttar NS, Lutzke L, Anderson M. Cutaneous photosensitivity after photodynamic therapy: is it really more common in sunny climates? Gastroenterology 118, A227 (2000).
61. Mang TS. Laser and light sources for PDT. Photodiag. Photodyn. Ther. 43-48 (2004).
62. Chen X, Yang CS. Esophageal adenocarcinoma a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 22, 1119-1129 (2001).
63. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am. J. Gastroenterol. 95, 2177-2184 (2000).
64. Wolfsen HC. Photodynamic therapy for mucosal esophageal adenocarcinoma and dysplastic Barrett's esophagus. Dig. Dis. 20, 5-17 (2002).
65. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig. Dis. Sci. 48, 1273-1283 (2003).
66. Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett's esophagus: reducing mortality from esophageal adenocarcinoma. Med. Clin. North Am. 89, 293-312 (2005).
67. Sampliner RE. Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J. Surg. 27, 1026-1029 (2003).
68. Sampliner RE. Management of premalignant esophagogastric lesions. Ariz. Med. 39, 312-313 (1982).
69. Garewal H, Ramsey L, Sharma P, Kraus K, Sampliner R, Fass R. Biomarker studies in reversed Barrett's esophagus. Am. J. Gastroenterol. 94, 2829-2833 (1999).
70. Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett's esophagus by laser ablation in an acid environment. Dig. Dis. Sci. 38, 365-368 (1993).
71. Brandt LJ, Kauvar DR. Laser-induced transient regression of Barrett's epithelium. Gastrointest. Endosc. 38, 619-622 (1992).
72. Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest. Endosc. 57, 567-579 (2003).
73. Conio M, Cameron AJ, Chak A, Blanchi S, Filiberti R. Endoscopic treatment of high-grade dysplasia and early cancer in Barrett's oesophagus. Lancet Oncol. 6, 311-321 (2005).
74. May A, Gossner L, Behrens A et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest. Endosc. 58, 167-175 (2003).
75. Rosch T, Sarbia M, Schumacher B et al. Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy 36, 788-801 (2004).
76. Ell C, May A, Gossner L et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118, 670-677 (2000).
77. Seewald S, Akaraviputh T, Seitz U et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest. Endosc. 57, 854-859 (2003).
78. Rajan E, Gostout CJ, Feitoza AB et al. Widespread EMR. A new technique for removal of large areas of mucosa. Gastrointest. Endosc. 60, 623-627 (2004).
79. Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am. J. Gastroenterol. 97, 2998-3006 (2002).
80. Schulz H, Miehlke S, Antos D et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest. Endosc. 51, 659-663 (2000).
81. van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RW, Tilanus HW. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am. J. Gastroenterol. 94, 1153-1160 (1999).
82. Gossner L, May A, Stolte M, Seitz G, Hahn EG, Ell C. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest. Endosc. 49, 8-12 (1999).
83. Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am. J. Surg. Pathol. 22, 239-245 (1998).
84. Salo JA, Salminen JT, Kiviluoto TA et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann. Surg. 227, 40-44 (1998).
85. Eisen GM. Ablation therapy for Barrett's esophagus. Gastrointest. Endosc. 58, 760-769 (2003).
86. Sampliner RE. Endoscopic ablative therapy for Barrett's esophagus: current status. Gastrointest. Endosc. 59, 66-69 (2004).
87. Grade AJ, Shah IA, Medlin SM, Ramirez FC. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. Gastrointest. Endosc. 50, 18-22 (1999).
88. Kahaleh M, Van Laethem JL, Nagy N, Cremer M, Deviere J. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 34, 950-955 (2002).
89. Byrne JP, Armstrong CR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am. J. Gastroenterol. 93, 1810-1815 (1998).
90. Ginsberg GG, Barkun AN, Bosco JJ et al. The argon plasma coagulator: February 2002. Gastrointest. Endosc. 55, 807-810 (2002).
91. Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 51, 776-780 (2002).
92. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest. Endosc. 44, 532-535 (1996).
93. Kovacs BJ, Chen YK, Lewis TD, DeGuzman LJ, Thompson KS. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest. Endosc. 49, 547-553 (1999).
94. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am. J. Gastroenterol. 92, 582-585 (1997).
95. Sampliner RE, Faigel D, Fennerty MB et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest. Endosc. 53, 554-558 (2001).
96. Dulai GS, Jensen DM, Cortina G, Fontana U, Ippoliti A. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest. Endosc. 61, 232-240 (2005).
97. Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment. Pharmacol. Ther. 20, 1289-1296 (2004).
98. Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed? J. Clin. Pathol. 52, 509-512 (1999).
99. Ganz RA, Utley DS, Stern RS, Jackson J, Batts KP, Termin P. Complete ablation of porcine esophageal epithelium using a balloon-based bipolar electrode. Gastrointest. Endosc. 59, AB250 (2004).
100. Sharma VK, Fleisher DE, Wang KK, Overholt B, Fennerty B. A randomized trial of radio-frequency ablation of specialized intestinal metaplasia of the esophagus. Gastrointest. Endosc. 59, AB113 (2004).
101. Grana L, Ablin RJ, Goldman S, Milhouse E Jr. Freezing of the esophagus: histological changes and immunological response. Int. Surg. 66, 295-301 (1981).
102. Dvorakova K, Payne CM, Ramsey L et al. Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues. Am. J. Gastroenterol. 100, 424-431 (2005).
103. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized Phase III trial. Gastrointest. Endosc. 62(4), 488-498 (2005).